摘要
目的观察吸入信必可[布地奈德/福莫特罗干粉剂（160/4.5μg）]对稳定期Ⅱ~Ⅲ级COPD患者的临床疗效。方法将明确诊断的60例COPD病人随机分为治疗组和对照组,治疗组给予吸入布地奈德/福莫特罗干粉剂;对照组予茶碱缓释片口服;疗程为6个月。治疗前后进行肺功能指标测定。结果治疗前,治疗组和对照组的FEV1/FVC和FEV1/预计值的差异无统计学意义（P〉0.05）。治疗结束时,治疗组FEV1/FVC和FEV1/预汁值较治疗前均有显著提高（P〈0.05）;对照组FEV1/FVC和FEV1/预计值与治疗前的差异无统计学意义（P〉0.05）。结论布地奈德/福莫特罗干粉吸入剂能够改善稳定期Ⅱ~Ⅲ级COPD患者的肺功能和生活质量,降低住院率。
To evaluate clinical efficacy of budesonide/fomoterol in single inhaler in treatment of patients with stable moderate to severe COPD）.Methods 60 patients with COPD were randomly divided into theray and control groups.Baseline treatments were similar in all patients.Patients in theray group received budesonide/fomoterol inhalation twice daily via Turbuhaler for 6 months.Slow-release theophylline twice daily was additionally given to patients in control group for 6 months.Before and after the therapeutic course,tests for lung function in patients of these two groups were examined and compared with each other.Results Before the experiment,difference of FEV1/FVC and FEV1/predictive value between these two groups was not significant（P0.05）.At the end of experiment,the values of FEV1/FVC and FEV1/predictive value in trial group increased in different extent than baseline values（P0.05）.But the change of values of FEV1/FVC and FEV1/predictive value in control group after the experiment was not significant（P0.05）.Conclusion Budesonide/fomoterol in single inhaler can improve lung function and life quality of patients with stable moderate to severe COPD,and it can also reduce the rate of hospitalization of these patients.
出处
《临床肺科杂志》
2011年第9期1370-1371,共2页
Journal of Clinical Pulmonary Medicine
